Recreating the Endocrine Niche: Advances in Bioengineering the Pancreas
Artificial Organs,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 23, 2025
Intrahepatic
islet
transplantation
is
a
promising
strategy
for
β-cell
replacement
therapy
in
the
treatment
of
Type
1
Diabetes.
However,
several
obstacles
hinder
long-term
efficacy
this
therapy.
A
major
challenge
scarcity
donor
organs.
During
isolation
process,
islets
are
disconnected
from
their
extracellular
matrix
(ECM)
and
vasculature,
leading
to
significant
loss
due
anoikis
hypoxia.
Additionally,
inflammatory
rejection
reactions
further
compromise
survival
engraftment
success.
Extensive
efforts
being
made
improve
transplantation.
These
strategies
include
promoting
revascularization
ECM
support
through
bioengineering
techniques,
exploring
alternative
sources
insulin-secreting
cells,
providing
immunomodulation
graft.
Despite
these
advancements,
gap
remains
integrating
into
cohesive
approach
that
effectively
replicates
native
endocrine
environment.
Specifically,
lack
comprehensive
methods
address
both
structural
functional
aspects
niche
limits
reproducibility
clinical
translation.
Therefore,
an
pancreas
must
aim
recreate
achieve
lifelong
insulin
independence.
This
review
discusses
various
developed
produce
building
blocks
generating
vascularized,
immune-protected
construct,
emphasizing
importance
niche's
composition
function.
Language: Английский
Can Islet Transplantation Possibly Reduce Mortality in Type 1 Diabetes
Cell Transplantation,
Journal Year:
2025,
Volume and Issue:
34
Published: Jan. 1, 2025
Islet
transplantation
(IT)
is
a
successful
natural
cell
therapy.
But
the
benefits
are
known
mostly
to
individuals
with
severe
type
1
diabetes
who
undergo
IT
and
health
care
professionals
that
work
make
therapy
available,
reproducible,
safe.
Data
linking
overall
survival
in
T1D
might
alter
this
situation
frame
more
positive
light.
Recent
analysis
of
mortality
several
cohorts
suggests
has
possible
when
used
alone
or
conjunction
renal
transplantation.
Multi-center
prospective
studies
long-term
follow-up
receive
stand-alone
versus
qualify
for
but
do
not
procedure
would
seem
reasonable
undertake
confirm
an
benefit.
Language: Английский
Advancing diabetes treatment: from human beta cell technology to bioartificial pancreas development
Joana Sá,
No information about this author
Simone C. Sá,
No information about this author
Hélène Leménager
No information about this author
et al.
Frontiers in Biomaterials Science,
Journal Year:
2025,
Volume and Issue:
4
Published: March 19, 2025
In
2021,
approximately
537
million
people
worldwide,
primarily
in
low-
and
middle-income
countries,
were
affected
by
diabetes,
leading
to
6.7
deaths
annually
or
severe
secondary
complications
including
life-threatening
hyperglycemia.
For
nearly
50
years,
current
therapeutic
approaches
include
full
pancreas
transplantation
isolated
pancreatic
islets,
more
recently,
cell
therapy
such
as
vitro
generated
islets
stem
derived.
The
of
islet
cells
can
be
less
invasive
than
organ
transplantation,
however,
does
not
achieve
the
same
rate
functional
success
due
low
survival
engrafted
cells.
Tissue-engineered
bioartificial
has
been
designed
address
issues,
improving
engraftment,
survival,
immune
rejection
problems,
with
added
advantage
that
tissue
produced
an
unlimited
source
material.
Language: Английский
Protocol for renal subcapsular islet transplantation in diabetic mice to induce long-term immune tolerance
STAR Protocols,
Journal Year:
2025,
Volume and Issue:
6(2), P. 103729 - 103729
Published: April 7, 2025
Language: Английский
Polymerized laminin-modified microcapsules improve pancreatic islet resilience towards cytokine induced inflammatory stress and lower chemoattractant cytokine secretion
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
unknown, P. 101812 - 101812
Published: May 1, 2025
Language: Английский